Validation: recovering the standard of care

In hundreds of diseases the corrective direction derived from untuned geometry independently recovers a treatment already in clinical use. Since gamma is never fitted, the agreement was not engineered, so each recovery validates the logic. The kit reports these as agreement with established practice, adds no dose, and makes no treatment claim of its own.

In 322 of 839 diseases the direction derived from pure geometry independently recovers a treatment already in clinical use. Because the geometry was never tuned, each recovery is a genuine validation signal for the logic — not a treatment claim by this kit.

Why a recovery counts as validation

The switch is built from promoter sequence with γ never fitted (see Method). When that untuned geometry then points the same way as an approved, mechanistically-understood medicine for the same disease, the agreement was not engineered in. Replicated across hundreds of independent diseases, these agreements are the main evidence that the corrective-direction logic is tracking real biology.

✓ Agreement, reported as agreement. Where an approved agent already exists, the page reports a match with established practice. The kit does not re-claim the medicine; it notes that its independent geometry recovered it.

Recovered standards — a representative sample

A sample of diseases where the forced corrective direction recovers an agent already in clinical use (status as pinned in the corpus; no dose, no efficacy magnitude). The full set is linked from every matching disease page.
diseasegenerecovered agent (direction-concordant)
AlkaptonuriaHGDHPD / 4-HPPD inhibitor (nitisinone / NTBC)
Acute intermittent porphyria OMIM 176000HMBSALAS1-knockdown siRNA (givosiran)
Atypical haemolytic uraemic syndromeCFHterminal-complement (anti-C5) monoclonal antibody (eculizumab; long-acting ravulizumab)
Achondroplasia OMIM 100800FGFR3CNP analogue (vosoritide)
Bardet-Biedl syndromeBBS1MC4R agonist (setmelanotide / Imcivree)
Beta-thalassaemiaHBBerythroid-maturation agent / activin-receptor ligand trap (luspatercept)
Spinal muscular atrophySMN1SMN2 splicing modifier (nusinersen -- ASO; risdiplam -- small molecule)
Wilson disease OMIM 277900ATP7Bcopper chelator (penicillamine / trientine)
PhenylketonuriaPAHPEGylated phenylalanine ammonia-lyase (pegvaliase)
Cystic fibrosis OMIM 219700CFTRCFTR potentiator (ivacaftor)
Gaucher disease OMIM 230800GBA1enzyme replacement (imiglucerase, velaglucerase alfa, taliglucerase alfa)
Fabry disease OMIM 301500GLAenzyme replacement (agalsidase beta, agalsidase alfa, pegunigalsidase alfa)
Pompe disease OMIM 232300GAAenzyme replacement (alglucosidase alfa, avalglucosidase alfa)
Hereditary angioedemaSERPING1plasma-kallikrein inhibitor (lanadelumab mAb / ecallantide / berotralstat)
Sickle cell disease OMIM 603903HBBBCL11A erythroid-enhancer disruption (exagamglogene autotemcel / exa-cel)
HADH hyperinsulinismHADHK-ATP-channel opening (diazoxide) suppressing the unregulated insulin-secretory drive
5-alpha reductase deficiencySRD5A2dihydrotestosterone replacement (topical/systemic) supplying the deficient androgen
Aromatic L-amino acid decarboxylaseDDCAAV2-hAADC putaminal gene therapy (eladocagene exuparvovec)
AbetalipoproteinemiaMTTPhigh-dose fat-soluble-vitamin substitution (vitamin E with A and K) supplying the deficient vitamins downstream of the MTTP lipoprotein-assembly defect
AceruloplasminemiaCPiron-chelation therapy (deferiprone or deferasirox) reducing the tissue iron accumulation of the ceruloplasmin-ferroxidase loss
Triple A / Allgrove syndromeAAASadrenal glucocorticoid replacement supplying the deficient cortisol output
Acrodermatitis enteropathicaSLC39A4oral zinc (zinc sulfate/gluconate replacement supplying the dietary zinc the SLC39A4 transporter can no longer absorb)
Adenine phosphoribosyltransferase deficiencyAPRTxanthine oxidase inhibitor (allopurinol; febuxostat) -- reduces 2,8-dihydroxyadenine production
Adenosine deaminase deficiencyADAex-vivo autologous CD34+ haematopoietic stem-cell gene therapy (ADA-gene-corrected autologous HSC; Strimvelis, EMA-approved 2016) -- DIRECT, restores the causal gene itself
ADPKDPKD2vasopressin-V2-receptor antagonism (tolvaptan) lowering the cAMP-driven cystogenic drive
Congenital afibrinogenemiaFGAfibrinogen-concentrate replacement therapy supplying the deficient fibrinogen clotting substrate
Arginine:glycine amidinotransferaseGATMcreatine monohydrate
Aicardi-Goutieres syndrome 5SAMHD1janus-kinase (JAK) inhibition opposing the constitutive type-I-interferon drive
Aicardi-Goutieres syndrome 2RNASEH2BJAK1/2 inhibition (baricitinib) reducing the type-I-interferon signalling over-activation (approved for other inflammatory indications; direction-only repurposing hypothesis)
Aicardi-Goutieres syndrome 1TREX1JAK inhibition (baricitinib) reducing the type-I-interferon signaling drive downstream of the TREX1 defect
Alagille syndromeJAG1ileal bile-acid transporter (IBAT/ASBT) inhibition (maralixibat) lowering the recirculating bile-acid load
Alpha-1-antitrypsin deficiency OMIM 613490SERPINA1alpha-1-antitrypsin augmentation (pooled human plasma A1AT)
Alpha-mannosidosisMAN2B1recombinant human alpha-mannosidase enzyme replacement (velmanase alfa / Lamzede, FDA 2023-02-16, the first approved therapy for alpha-mannosidosis) -- DIRECT on the MAN2B1 gene product
Alport autosomalCOL4A3renin-angiotensin-aldosterone-system antagonism (ACE inhibition) lowering intraglomerular pressure
Alport autosomalCOL4A4renin-angiotensin-aldosterone-system antagonism (ACE inhibition) lowering intraglomerular pressure
Alport syndrome X-linkedCOL4A5renin-angiotensin system antagonism (ACE inhibition) reducing glomerular hyperfiltration downstream of the COL4A5 basement-membrane defect
Autoimmune lymphoproliferative syndromeFASmTOR inhibition (sirolimus) reducing the lymphoproliferative effector drive of the FAS apoptosis defect
Alternating hemiplegia of childhoodATP1A3calcium-channel modulation (flunarizine) reducing the paroxysmal episode burden in the ATP1A3 Na/K-ATPase channelopathy
Andersen-Tawil syndromeKCNJ2class-IC antiarrhythmic (flecainide)
Androgen insensitivityARsex-steroid hormone replacement (supportive, after gonadectomy where indicated)
Apparent mineralocorticoid excessHSD11B2mineralocorticoid-receptor antagonism (spironolactone-class) opposing the unopposed cortisol mineralocorticoid drive
DOCK8 deficiency / autosomal recessive hyper-IgE syndrome…DOCK8allogeneic haematopoietic-stem-cell transplantation supplying DOCK8-competent lymphoid lineages, restoring immune function
Argininemia / arginase-1 deficiencyARG1dietary protein restriction with nitrogen-scavenging therapy (lowering the arginine and ammonia load the deficient ARG1 arginase can no longer clear; pegzilarginase enzyme substitution under study)
Argininosuccinic aciduriaASLnitrogen scavenger (sodium phenylbutyrate / glycerol phenylbutyrate); arginine supplementation
Aromatase deficiencyCYP19A1oestrogen replacement therapy supplying the oestrogen the deficient CYP19A1 aromatase can no longer synthesise
Artemis-deficient severe combined immunodeficiencyDCLRE1Callogeneic or lentiviral-gene-modified haematopoietic-stem-cell transplantation supplying Artemis-competent lymphoid lineages, reconstituting immunity
ARVCDSG2beta-adrenergic antagonism with exercise restriction reducing the arrhythmic adrenergic drive
ARVCDSPbeta-adrenergic antagonism with exercise restriction reducing the arrhythmic adrenergic drive

This is a sample; the complete agreement set spans all 322 matching diseases, each carrying the agreement callout on its own page. Candidate-level, 147 of 233 surfaced rows are explicit rediscoveries.

Still not a prescription. A recovered match means the direction agrees with medicine an expert may already use under proper care. It does not authorise anyone to self-administer, and it adds no dose.